Why zero markup matters

Telehealth unit economics are usually decided in the pharmacy line, not the marketing line. Founders will argue over acquisition cost to the dollar and then sign a platform agreement in which the medication their patients take every month carries a medication markup, plus a share of top-line revenue. Both charges look small at signing, when volume is small. Both are priced as a percentage of the thing the brand is trying to grow, so they scale with it.

This post works through what markup and revenue share do to a telehealth brand's numbers at 1,000 patients and again at 5,000, using one hypothetical program. The guide to what 0% pharmacy markup means covers how to check a markup claim on a single fill; the argument here is about what the percentage does over a year.

How telehealth platforms get paid

A white-label telehealth platform, meaning a vendor that supplies the providers, pharmacy access and software under a brand's name, has three ways to earn money. It can take a spread on medication, buying at wholesale and billing the brand a higher price. It can take a percentage of the brand's revenue. Or it can charge flat fees: a setup fee, a monthly fee and a fixed amount per consult or per order.

The first two are easier to sell. They keep the fixed cost low and come with the line "the platform only wins when the brand wins." The line is true in the least useful sense. The vendor wins a percentage of every win, every month, without its own costs rising to match. A pharmacy fill costs the vendor about the same to process whether the brand has 200 patients or 20,000, so the spread on fill number 20,000 is close to pure margin. A flat model is harder to sell and easier to build a company on, because the platform cost stays close to fixed while the brand's revenue compounds.

Where medication markup hides

Markup rarely appears as a line called markup. It appears as the medication price on the platform's rate card, presented as a single figure with no wholesale price beside it. The wholesale figure is the price the pharmacy pays or charges at cost, sometimes called wholesale acquisition cost, and a brand that never sees it cannot know the spread. Pass-through means the brand is billed that wholesale figure, with the pharmacy's dispensing and shipping fees stated separately, and the platform adds nothing on top.

Two other places to look. Some agreements state 0% markup on medication and then add a per-order fee, a monthly minimum or a "pharmacy services" charge that rises with fills, which is a markup by another name. Others give the brand a wholesale price at signing and reserve the right to change it, so the spread reappears at renewal. The test is simple to state: can the brand see the wholesale price on every invoice, and does the total the brand pays per fill stay flat as fills grow?

A worked example at 1,000 patients

Take a hypothetical weight-loss brand with 1,000 active patients on a program billed at $199 a month, where the medication costs about $140 a month at wholesale. Assume, for the example only, a marked-up agreement that charges 30% on medication and a 10% revenue share. Those percentages are assumptions chosen to make the arithmetic easy, not a report of any vendor's terms.

• Medication markup: 30% of $140 is $42 per patient per month, or $42,000 a month across the book.
• Revenue share: 10% of $199 is about $20 per patient per month, another $20,000 a month.
• Platform take: roughly $62,000 a month, or about $744,000 a year, before any fixed fees.

Now run the same brand on wholesale pass-through with flat fees. Medication is billed at the $140 wholesale price. The brand pays a fixed monthly platform fee, say $2,000, and a flat fee per completed consult. Not every patient needs a consult every month; a stable patient on a maintenance dose may be reviewed every few months, while a new patient needs an initial visit and follow-ups during dose changes. Assume those 1,000 patients generate about 400 completed consults a month, and price each at $25.

• Consults: 400 at $25 is $10,000 a month.
• Platform fee: $2,000 a month.
• Platform take: $12,000 a month, or $144,000 a year.

The flat model costs about a fifth of the marked-up one at this size. The more important point is the direction of travel. Consults grow more slowly than patient count, because the share of stable patients rises as the book matures, so the flat model's cost per patient falls as the brand grows while the marked-up model's cost per patient stays exactly where it started.

The same brand at 5,000 patients

Scale the example by five. On the marked-up agreement, medication markup is $210,000 a month and revenue share is close to $100,000, so the platform takes about $310,000 a month, or roughly $3.7 million a year. That is the economics of a co-founder's stake, paid out of operating cash to a vendor that owns none of the brand.

On the flat model, 5,000 patients might generate around 2,000 consults a month, or $50,000, plus the $2,000 fee, for about $52,000 a month or $624,000 a year. The gap between the two models has grown from about $50,000 a month to about $258,000 a month. Every patient added widens it, because one model charges a percentage of each patient's spend for as long as the patient stays and the other charges for work done.

This is also why the marked-up model is hard to leave. A brand at 5,000 patients that wants to move has to migrate its patients' prescriptions and its pharmacy relationship at once, and the vendor holding the spread knows it. A brand that pays wholesale and flat fees from the start can model its exit as easily as its growth. The unit economics calculator lets an operator try different consult rates and program prices against the same structure.

Percentages feel painless at low volume. They are priced against the brand's success: the platform's take grows with revenue while its costs stay flat.

Revenue share on a telehealth platform compounds the same way

Revenue share deserves separate treatment because it is often presented as the fairer of the two charges. It taxes the whole program price rather than the medication, so it also grows when the brand raises prices, adds a lab panel, or sells a second program to the same patient. Every improvement in the brand's own pricing sends a slice to the vendor. A brand that does not need the platform's capital has no reason to give away a percentage of its revenue for services it could pay for at cost.

There is a legal dimension as well. In states that enforce fee-splitting rules, a management fee set as a percentage of clinical revenue can draw scrutiny in ways a flat fee for services rendered does not. The comparison of flat fees and revenue share walks through when a percentage can make sense and where it creates exposure.

Markup bends clinical decisions

There is a second-order cost that does not appear in a spreadsheet. A platform that earns a spread on each fill has a financial opinion about what gets prescribed, how often, and at what dose. Its product list drifts toward the items with the widest spread; its protocols drift toward more frequent fills; its retention messaging leans on the medication rather than the outcome. None of this requires bad intent. Margin pressure steers on its own, one product decision at a time.

Wholesale pass-through takes the platform out of the decision. The prescriber chooses the medication on clinical grounds, the pharmacy fills it at cost, and nobody upstream earns more if the dose goes up or the patient stays on medication longer than needed. For a brand whose reputation depends on patient outcomes, that separation is worth more than the money.

Questions to ask before signing

• What is the medication markup, in percentage terms, in writing, and does the invoice show the wholesale price beside the billed price?
• Is there any revenue share, monthly minimum, per-order fee or pharmacy services charge that scales with fills or revenue?
• Can the wholesale price change during the term, and on what notice?
• What do the per-patient economics look like at ten times current volume, using the agreement's own terms?
• If the brand leaves, what do its patients pay for the same medication the following month, and who holds the pharmacy relationship?

A vendor with clean economics answers all five in one email. A vendor that earns its margin in the spread needs a call to walk through it, and the walk-through usually includes the phrase "it depends on volume."

Tessic Health publishes its terms for this reason: a one-time setup fee, a monthly fee from $1,000, $25 per completed consult, medication at wholesale with 0% markup, and no revenue share on any plan, month to month after setup. The full schedule is on the pricing page. Founders should be able to model a clinic at 10,000 patients before it has 100, and the fee model that survives that spreadsheet is the one that deserves to run the clinic.

Questions operators ask

Is a 0% medication markup the same as the cheapest medication? No. Zero markup means the platform adds nothing to the wholesale price; the wholesale price itself depends on the pharmacy, the product and the volume the pharmacy network buys at. Two platforms can both be at 0% and bill different wholesale prices. The right comparison is the wholesale price on the invoice, not the markup claim.

Does wholesale pharmacy pass-through mean the brand handles the pharmacy itself? No. Pass-through describes the billing, not the operations. The platform or its pharmacy network still dispenses and ships; it bills the brand the wholesale cost with fees stated separately instead of a blended price.

Can a revenue share be worth it early on? For a brand with no capital that needs the platform to carry costs it cannot cover, sometimes. The condition is a cap or a conversion to flat fees at a defined volume, in writing. Without that clause, the early discount becomes the most expensive financing the brand ever takes.

How should an operator model markup and revenue share side by side? Build the model per patient per month, split fixed and variable platform costs, and run it at current volume, five times and ten times. If the variable platform cost per patient does not fall as the brand grows, the agreement is taxing growth.